Assessment of Look-Alike, Sound-Alike Similarities Among BrandNames of Tablets and Capsules: A Cross-Sectional Survey inThailand
Main Article Content
Keywords
look-alike, sound-alike, lasa, brand names, matching, similarity, thailand
Abstract
Background: Look-Alike, Sound-Alike (LASA) drugs pose significant risks to patient safety due to potential medication errors, primarily from confusion over drug names. Such issues are of global concern and are pervasive across healthcare settings. Objective: This study evaluated the similarity between the registered brand names of medication, specifically focusing on tablets and capsules that are commercially accessible in Thailand. Methods: This research analyzed secondary data from Thailand’s Bureau of Drug Administration, focusing on tablets and capsules drugs. An orthographic analysis of the 18,108 registered items (as of January 2020) was performed, and similarities and differences were analyzed using Microsoft Excel. Attributes such as registration number, manufacturer details, active ingredients, dosage forms, and strength were considered when categorizing similar names. Results: Upon analyzing 18,108 registered tablets and capsules, four groups emerged from pairwise brand name similarity analysis: 1. Matching brand names from one pharmaceutical company with identical active pharmaceutical ingredients (APIs) but multiple registration numbers (66.47%). 2. Matching brand names from various pharmaceutical companies with the same active ingredients (33.03%). 3. Matching brand names from different pharmaceutical companies with different active ingredients (0.39%). 4. Matching brand names from the same pharmaceutical company with different active ingredients (0.11%). The “Tall Man Letter” principle was leveraged to examine potential resemblances among 18,108 Thai pharmaceutical brand names. Twelve terms exhibited notable similarities, with “AMINE,” “HYDRO,” and “PREDNIS” appearing most frequently. Conclusion: These results underscore the prevalence of LASA issues in drug brand names, potentially leading to confusion and errors in medication use, and highlight the need for system improvements to enhance patient safety.
References
2. Napaporn J, Buakaew P, Suksakornthanawat P, et al. Analogous comparison of registered brand name drugs of tablets and capsules commercially available in Thailand: A retrospective study. PLOS ONE. 2022;17(10):e0276321. https://doi.org/10.1371/journal.pone.0276321
3. Chanakit T, Napaporn J, Chiempattanakajohn T, et al. The survey of look alike/sound alike (LASA) drugs available in hospitals in Thailand. Afr J Pharm Pharmacol. 2013;7(6):227-239.
4. Bryan R, Aronson JK, Williams AJ, et al. A systematic literature review of LASA error interventions. Br J Clin Pharmacol. 2021;87(2):336-351. https://doi.org/10.1111/bcp.14644
5. Bryan R, Aronson JK, Williams A, et al. The problem of look-alike, sound-alike name errors: Drivers and solutions. Br J Clin Pharmacol. 2021;87(2):386-394. https://doi.org/10.1111/bcp.14285
6. Bryan R, Aronson JK, ten Hacken P, et al. Patient Safety in Medication Nomenclature: Orthographic and Semantic Properties of International Nonproprietary Names. PLOS ONE. 2015;10(12):e0145431. https://doi.org/10.1371/journal.pone.0145431
7. The World Health Organization. (2007). WHO launches ‘Nine patient safety solutions’. https://www.who.int/news/item/02-05-2007-who-launches-nine-patient-safety-solutions Accessed 12 Aug, 2022.
8. The World Health Organization. (1997). Guidance on INN. https://www.who.int/medicines/services/inn/innquidance/en/Accessed 24 Dec, 2021.
9. International Pharmaceutical Federation (FIP). Pharmacists’ Role in Medication Without Harm. The Hague, The Netherlands:International Pharmaceutical Federation; 2020.
10. Institute for Safe Medication Practices (ISMP). (2009). Survey on LASA drug name pairs: who knows what’s on your list and the best ways to prevent mix-ups? Accessed 15 May, 2023.
11. Goedecke T, Ord K, Newbould V, et al. Medication errors: new EU good practice guide on risk minimisation and error prevention. Drug safety. 2016;39:491-500. https://doi.org/10.1007/s40264-016-0410-4
12. European Medicines Agency (EMA). (2021). Recommendations on medication errors. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medication-errors/recommendations-medication-errors Accessed 01 August, 2023.
13. The Association of Hospital Pharmacist (Thailand). (2020). Framework of hospital drug system. https://www.thaihp. org/?fbclid=IwAR1itl_pQ0hVUnrJEyNBzfI_OBKIvUbos2QeTzhVQBtG1KDFGnaZxFtJN0U Accessed 6 Aug, 2022.
14. Chumchit C, Amrumpai Y, Treesak C. Recognition on medication safety and look-alike/sound-alike medication problems in Thai public hospitals. Silpakorn U Science & Tech J. 2015;9(2):40-51.
15. Wongboonnak P. Look-alike sound-alike drugs situation in Thailand. HCU Journal of Health Science. 2018;22:205-216.
16. Clark KR, Vealé BL. Strategies to enhance data collection and analysis in qualitative research. Radiol Technol. 2018;89(5):482ct-485ct.
17. Hsieh H-F, Shannon SE. Three approaches to qualitative content analysis. Qualitative Health Research. 2005;15(9):1277-1288.https://doi.org/10.1177/1049732305276687
18. Jitruknatee A, Martro J, Tosanguan K, et al. National drug policies in Thailand: evolution and lessons for the future. J HealthSci. 2020:S3-S14.
19. Pitaknitinun K, Lawanprasert Y, Vimolkittipong S. Thailand’s legal framework concerning drugs. Journal of Health Science.2020:S15-S30. https://doi.org/10.7717/peerj.12809
20. Reker D, Blum SM, Steiger C, et al. “Inactive” ingredients in oral medications. Sci Transl Med. 2019;11(483). https://doi.org/10.1126/scitranslmed.aau6753
21. Merchant L, Lutter R, Chang S. Identical or similar brand names used in different countries for medications with different active ingredients: a descriptive analysis. BMJ Qual Saf. 2020;29(12):988-991. https://doi.org/10.1136/bmjqs-2019-010316
22. Schrader T, Tetzlaff L, Beck E, et al.The similarity of drug names as a possible cause of confusion: Analysis of data from outpatient care. Z Evid Fortbild Qual Gesundhwes. 2020;150-152:29-37. https://doi.org/10.1016/j.zefq.2020.01.006
23. Lambert BL, Galanter W, Liu KL, et al. Automated detection of wrong-drug prescribing errors. BMJ Qual Saf. 2019;28(11):908-915. https://doi.org/10.1136/bmjqs-2019-009420
24. Filik R, Purdy K, Gale A, et al. Drug name confusion: evaluating the effectiveness of capital (“Tall Man”) letters using eye movement data. Soc Sci Med. 2004;59(12):2597-2601. https://doi.org/10.1016/j.socscimed.2004.04.008
25. Institute for Safe Medication Practices (ISMP). (2019). ISMP List of Confused Drug Names. https://www.ismp.org/recommendations/confused-drug-names-list Accessed 11 Oct, 2022.
26. Raynor DK, Blenkinsopp A, Knapp P, et al. A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines. Health Technol Assess. 2007;11(5):iii,1-160. https://doi.org/10.3310/hta11050
27. La Caze A. Safer dispensing labels for prescription medicines. Aust Prescr. 2018;41(2):46-49. https://doi.org/10.18773/austprescr.2018.009
28. Grissinger M. Multiple brand names for the same generic drug can cause confusion. P t. 2013;38(6):305. http://www.ncbi.nlm.nih.gov/pmc/articles/pmc3737992/
29. Emmerton LM, Rizk MF. Look-alike and sound-alike medicines: risks and ‘solutions’. Int J Clin Pharm. 2012;34(1):4-8. https://doi.org/10.1007/s11096-011-9595-x
30. Galanter WL, Bryson ML, Falck S, et al. Indication alerts intercept drug name confusion errors during computerized entry of medication orders. PLOS ONE. 2014;9(7):e101977. https://doi.org/10.1371/journal.pone.0101977
31. U.S. Department of Health and Human Services Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). (2015). Size, shape, and other physical attributes of generic tablets and capsules. https://www.fda.gov/files/drugs/published/Size--Shape--and-Other-Physical-Attributes-of-Generic-Tablets-and-Capsules.pdf Accessed 10 Jan, 2022.
32. Rider BB, Mehta H, Merchant L. Special considerations for proprietary name review: focus on products That may be prescribed “As Directed”. Ther Innov Regul Sci. 2019;53(3):381-386. https://doi.org/10.1177/2168479018782669
33. Karet GB. Linguistic analysis of generic-generic drug name pairs prone to wrong-drug errors for which Tall-Man lettering is recommended. Ther Innov Regul Sci. 2023;57(4):751-758. https://doi.org/10.1007/s43441-023-00526-0
34. Government of Canada. (2014). Guidance document for industry - review of drug brand names. https://www.canada.ca/en/health-canada/services/drugs-health-products/reports-publications/medeffect-canada/guidance-document-industry-reviewdrug-brand-names.html Accessed 6 August, 2022.
35. Khontum A, Chanthapasa K. Perceptions of communities regarding look-twin sound-twin drugs: a case study of a Sub-District in the Northeastern Region of Thailand. Risk Manag Healthc Policy. 2021;14:2345-2355. https://doi.org/10.2147/rmhp.s303899
36. Lizano-Díez I, Figueiredo-Escribá C, Piñero-López M, et al. Prevention strategies to identify LASA errors: building and sustaining a culture of patient safety. BMC Health Serv Res. 2020;20(1):63. https://doi.org/10.1186/s12913-020-4922-3
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.